Non-myeloablative regimens have been proven to allow engraftment following allogeneic stem cells transplantation (allo-SCT) with minimal procedure-related toxicity. Conventional allo-SCT may produce remissions in patients with relapsed and refractory lymphoid malignancies (LM) but these good results may be achieved at the cost of high treatment-related morbidity and mortality. Application of allo-SCT using less intensive regimens may temper the frequency of these complications, allowing a potent graft-versus-tumor effect (GVT). We present our data on 11 patients with LM receiving allo-SCT with a reduced regimen. Ten patients had received previous high-dose therapy, and were at high risk for toxicity, thus precluding the use of allo-SCT. A fludarabine and low-dose busulfan combination facilitated engraftment while exerting GVT. Hematological recovery was quick, and full donor T cell chimerism preceded acute GVHD. GVHD and infections were the major problems. Spontaneous acute GVHD occurred in eight patients (72%). Five patients (45%) achieved complete remission, and the GVT effect was closely associated with GVHD. These results support the concept that GVT is effective against LM in patients who have been heavily pretreated. Further studies are needed to investigate strategies to generate more specific alloreactive effects providing optimal GVT and an acceptable risk of GVHD and infections. Bone Marrow Transplantation (2001) 28, 335-339. Keywords: allogeneic stem cells transplantation; nonmyeloablative conditioning; GVT; GVHD; lymphoid malignancy Despite its hazardous immediate and late complications, allogeneic stem cell transplantation (allo-SCT) offers an important anti-leukemic and anti-tumoral advantage due to
the alloreactivity against host tumor cells. 1, 2 Non-myeloablative and reduced conditioning regimens have recently been proven to allow engraftment following allo-SCT with minimal procedure-related toxicity in patients with advanced disease. 3 The immune reaction between donorderived immunocompetent T lymphocytes and host-type tumor cells has been well established to be the major antitumor agent in allo-SCT. 1 Evidence supporting the socalled graft-versus-tumor (GVT) effect includes the higher risk of relapse following T cell-depleted or syngeneic transplantation. 4, 5 Furthermore, donor lymphocyte infusions (DLI) may re-induce remission in many patients relapsing after allo-SCT. 6 New approaches using non-myeloablative and reduced conditioning regimens aim to extend the use of allo-SCT to patients who are ineligible for high-dose chemotherapy or total body irradiation by prioritizing and increasing the immunosuppressive aspect of the preparation.
Multiple myeloma (MM) is a lymphoid malignancy (LM) with a median survival of 3 years. Despite the development of numerous conventional chemotherapy regimens, there has been little progress in improving the survival of patients with MM. High-dose chemotherapy with autologous stem cell transplantation (ASCT) can result in prolonged survival, 7 but unfortunately, few, if any, patients with MM who receive ASCT are cured. 8 Only allo-SCT is curative in MM. However, the very high transplant-related morbidity and mortality limit the application of allo-SCT to younger patients. Allo-SCT has also produced prolonged remissions in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) and indolent LM. 9 As in MM, these good results are achieved at the cost of high treatment-related morbidity and mortality. Application of allo-SCT using reduced and less intensive conditioning regimens may temper the frequency of these complications in patients with LM, allowing sustained long-term diseasefree survival. We describe our data on 11 heavily pretreated patients with LM receiving allo-SCT with a reduced conditioning regimen.
Patients and methods
From January 1998 to September 1999, 11 patients (seven males and four females) with LM were treated with a combination of fludarabine and busulfan. The first three patients in this series received in addition anti-T-lymphocyte globulin (ATG). Patient characteristics are summarized in Table 1 . Briefly, the median age was 49 years (range, 40 to 62 years). Median time to transplantation from diagnosis was 45 months (range, 21 to 161 months). The 11 patients would not have been considered eligible for conventional allo-SCT in our institution due to age, disease status and poor performance status. Prior to allo-SCT, 10 patients out of 11 had received ASCT in the course of their disease. All patients were refractory to salvage chemotherapy and were treated as inpatients in private rooms.
The conditioning regimen included fludarabine (Fludara; Schering, Lys-Lez Lannoy, France) 25 mg/m 2 for 5 consecutive days (administered intravenously over 30 min from day −12 to −8), oral busulfan 2 mg/kg/day for 2 consecutive days (days −7 to −6). The first three patients (UPN 1, 2 and 3) also received ATG (Thymoglobuline; ImtixPasteur Merieux, Lyon, France) 2.5 mg/kg/day for 4 consecutive days (administered intravenously over 6 to 8 h). Supportive care was similar to our previous practice for many years, and included oral gut decontamination with colistine and nystatine. Pneumocystis carinii prophylaxis included trimethoprim/sulfamethoxazole (10 mg/kg/day trimethoprim) administered pre-transplantation (days −10 to −1) and as soon as the ANC exceeded 0.5 × 10 9 /l (7 mg/kg/day) twice weekly. Prophylaxis for herpes simplex virus included intravenous acyclovir 250 mg × 3/day starting on day +1 to day +7. Broad-spectrum antibiotics were begun for a fever greater than 38.5°C or clinical signs of infection. When necessary, the hemoglobin was maintained at a level of 8 g/dl and the platelet count at 20 × 10 9 /l with filtered, leukocyte-depleted and irradiated blood products. All patients received heparin at a dose of 1 mg/kg/day from day −12 until the ANC reached 0.5 × 10 9 /l, to prevent veno-occlusive disease (VOD). GVHD prophylaxis consisted of steroids 1 mg/kg/day from day +7 to day +30, and cyclosporin A (CsA) at a dose of 2 mg/kg/day by continuous intravenous infusion changed to oral as soon as tolerated. CsA doses were adapted to serum levels and to renal function. Patients were assessed systematically twice per week for CMV infection by antigenemia assay (CINAkit; Argene Biosoft, Varilhes, France). This method uses a monoclonal antibody pool which recognizes the lower matrix structural phosphoprotein pp65; in a positive specimen, results are reported as number of antigen positive cells and the patient was considered positive when having at least 2 infected cells out of 2 × 10 5 leukocytes), in order to initiate preemptive ganciclovir therapy. Seven donor-recipient pairs were CMV seropositive prior to transplantation.
All donors were HLA-compatible siblings. Only one donor-recipient pair was sex-mismatched. Chimerism status was assessed systematically between days 30 and 60, days 60 and 90 and days 90 and 180 following allo-SCT by microchimerism analysis. An average of five DNA polymorphic markers were tested for each donor-recipient pair in order to find at least one informative model. Informative models are characterized by the presence of PCR products of the smallest size in the recipient cell population.
Our first three transplanted patients (UPN 1, 2 and 3) received bone marrow grafts, but for the remaining eight patients, we chose to collect peripheral blood stem cells which may correlate with an increased GVT effect, rather than bone marrow. 
Results

Toxicity
The conditioning regimen was well tolerated. All patients survived beyond day 30 and maintained good oral intake throughout the procedure. None of the patients developed VOD or showed evidence of hepatic abnormalities.
Engraftment
All patients achieved an ANC greater than 0.5 × 10 9 /l at a median of 3 days post transplantation (range, 0 to 18 days). Platelet counts of 20.0 × 10 9 /l or greater without transfusion were reached at a median of 1 day (range, 0 to 10 days).
GVHD
Acute GVHD (two grade 1, four grade 3 and two grade 4) occurred in eight patients (72%), at a median time of 51 days (range, 14 to 98 days). UPN 2, 3 and 4 with no spontaneous GVHD and with rapidly progressing tumors received a donor leukocyte infusion (DLI of 1 × 10 7 CD3 cells/kg). UPN 2 developed grade 4 cutaneous and hepatic acute GVHD 22 days later. UPN 3 developed grade 2 gastrointestinal acute GVHD and UPN 4 developed grade 3 cutaneous and gastrointestinal acute GVHD following DLI.
Viral infections
The different events are summarized in Table 2 . Forty-five per cent of the patients developed CMV blood infections at a median of 38 days post transplantation (range, 10 to 180 days). These five patients did not develop clinical signs or symptoms attributable to CMV infection. Using the antigenemia assay, there was a median of 15 infected leukocytes (range, 2 to 19 leukocytes). All patients were treated with ganciclovir at a standard dose of 5 mg/kg twice daily for 14 days. None of the patients received maintenance therapy with ganciclovir. For all patients, antigenemia was cleared at a median time of 7 days after the onset of treatment.
Bacterial infections
During the period of neutropenia, no patient in our series encountered any bacterial infection. Nevertheless, four patients (36%) developed late bacterial infections. The median time for onset of bacterial infection was 143 days (range, 80 to 372 days). Blood cultures from these patients revealed two gram-negative bacteria (Citrobacter freundii -14  --7  4  85  127  17  3  123  G+  8  3  3 9  --2  --9  3  9 8  --15  162  G+  10  1  18  180  2  3  --11  3 These four patients had recovered a normal neutrophil count at the time of the septicemia. At time of these bacterial infections, patients were not receiving prophylactic antibiotics, but still had tunnelled lines in situ. Apart from the Staphylococcus epidermidis septicemia, tunnelled lines could not formally be considered to be the source of infection. All four patients responded rapidly to appropriate antimicrobial therapy.
Fungal infections
Four patients in our series (36%) developed Aspergillus fumigatus antigenemia at a median of 125 days (range, 60 to 372 days) following allo-SCT, but invasive pulmonary aspergillosis could not be formally documented.
Chimerism
Results are summarized in Table 3 . Between day 30 and day 60 following allo-SCT, only three patients (27%) reached full donor chimerism (UPN 4, 7 and 9). Between day 60 and 90, another two patients (UPN 5 and 6) from the series reached full donor chimerism. By day 180, seven (77%) out of nine evaluable patients had full donor chimerism. Lineage-specific chimerism analysis (CD3 + and CD14 + populations) was performed in six patients (UPN 6, 7, 8, 9, 10 and 11). T cell engraftment appeared to be more rapid than myeloid chimerism which increased gradually and overtook recipient hematopoiesis.
Response and survival
For patients with lymphomas and CLL, a complete response (CR) was defined as disappearance of all clinical and radiological evidence of active disease for a minimum of 3 consecutive weeks. Progressive disease was defined as the presence of clinical and radiological evidence of disease progression post transplantation. For patients with MM, response was judged on the basis of a decline in the level of paraprotein in serum or urine of at least 25%, 50%, 75%, or 90% on two occasions at least 6 weeks apart. Patients with a reduction of less than 25% were considered to have 
Bone Marrow Transplantation had no response to therapy. MM patients were considered to be in CR, when they had achieved at least 90% reduction in serum or urine paraproteins levels. At the time of latest follow-up, the median follow-up was 501 days (range, 108 to 942 days). Three patients remain alive: UPN 10 is disease-free with good quality of life, UPN 11 is in partial response and the third surviving patient (UPN 5) has active disease. Four deaths (UPN 3, 6, 8 and 9) were attributed to relapse or progressive disease. Four patients (UPN 1, 2, 4 and 7) died of GVHD while in complete remission which was refractory to steroids and ATG. Five patients (45%) achieved complete remission. In patients achieving complete remission there was a direct correlation between response and GVHD. Figure 1 represents the evolution of the monoclonal component (MC) following allo-SCT in UPN 4: this case provides evidence that the GVT effect overlaps with GVHD to some extent. Responses and outcomes for each patient are shown in Table 4 .
Discussion
Data from Slavin et al 3 and from other groups reported the feasibility of non-myeloablative and highly immunosuppressive conditioning regimens in patients with hematolog- ical malignancies. The rationale for such strategies is to induce efficient and potent immunotherapy mediated by allogeneic lymphocytes, and to offer patients a significant improvement in terms of quality of life, cost-effectiveness and disease-free survival. Our data are in accordance with those previously published as for low-toxicity regimens. While allo-SCT for advanced LM has been associated with a high early mortality, 12 and although all 11 patients in our series had risk features for toxicity that precluded the use of high-dose chemoradiotherapy, no direct regimen-related toxic deaths or grade 3 or 4 toxicity were observed in the early period post transplantation. Furthermore, hematological recovery in our cohort seemed quick compared to larger series using conventional myeloablative regimens.
Such dose-reduced regimens aim to provide sufficient immunosuppression to prevent graft rejection and allow sustained engraftment. Nevertheless, the immunosuppressive dose of the most commonly used agents necessary to allow engraftment of allogeneic stem cells is not well defined. This dose may vary from patient to patient and may depend on the degree of HLA compatibility between host and recipient, as well as on stem cells dose, T cell content of the graft and probably on prior therapy to which a patient has been exposed. 13 Ten out of 11 patients in our cohort received at least one ASCT before allo-SCT and therefore might be considered profoundly immunosupressed at the time of allo-SCT. For these reasons, apart from in the first three patients, we elected to avoid ATG. In the remaining eight patients, a fludarabine and low-dose busulfan combination alone without ATG, facilitated engraftment while exerting a GVT effect.
Chimerism studies showed that all patients had evidence of donor cell engraftment, and none rejected the transplant or had recovery of autologous hematopoiesis. Donor myeloid chimerism gradually replaced recipient hematopoiesis. T cell engraftment was more rapid, with full donor chimerism in five patients (45%) between day 60 and 90 and in 77% of patients between day 90 and 180. Full donor T cell chimerism preceded acute GVHD and disease regression, consistent with the requirement for full donor T cell chimerism for potent expression of a GVT effect. These results emphasize the importance of lineage-specific chimerism analysis to successfully monitor engraftment and any GVT effect following nonmyeloablative allo-SCT therapy.
GVHD and a high rate of late secondary infections were the major problems with this treatment. Among our 11 patients, we observed an incidence of 45% of early CMV infection occurring at a median of 38 days following transplantation. The median number of positive cells (CMV antigenemia (Ag)) at diagnosis was 15. CMV Ag proved to be a sensitive, specific and rapid technique for early diagnosis of CMV infection after allo-SCT.
14 This technique seems to reflect viral load in the systemic circulation, and high numbers of CMV antigen positive cells are associated with considerable transplant-related mortality. 15 Although high in comparison to other series, the rate of CMV infection and the Ag results (median, 15 cells) observed in our cohort is intriguing and do not seem to correlate with CMV-related mortality. Relative to viral infections, bacterial infections predominate in the early recovery phase post allo-SCT and bacterial pathogens account for more than 90% of the first infections during neutropenia. Our data suggest a different profile since no bacterial infections were documented during neutropenia, while we observed four late, severe septicemias (36%) occurring at a median of 143 days. All these bacterial infections occurred when patients had full neutrophil recovery. Although patients in our series had active GVHD or disease which usually favors infections, this high rate of secondary microbial infections is in accordance with data published by another group, 16 and may reflect the prolonged state of profound immune depression in patients previously autografted and receiving highly immunosuppressive agents such as fludarabine.
The other major problem in this setting was the high incidence of acute GVHD. Despite the use of short-term prophylaxis including CsA and steroids, severe grade 3 and 4 acute GVHD involving gut or liver occurred in six patients (54%), and following DLI in three further patients. In the myeloablative setting, acute GVHD is the consequence of the conditioning regimen and alloreactivity of the donor graft. 17 The use of a less ablative and toxic conditioning regimen does not seem in our study to reduce GVHD. The severity of GVHD in our patients is probably due to the potent alloreactive effects of the donor graft. The GVT effect was closely associated with this severe GVHD requiring aggressive therapy with high-dose steroids and ATG. The GVHD and the GVT effects appear to be intimately related in responding patients. The response profile in our MM patient (UPN 4) gives direct evidence of this correlation and of a powerful graft-versus-myeloma effect after non-myeloablative allo-SCT. Nevertheless, approaches to potentially reduce the risk of toxic GVHD and its separation from the beneficial GVT effect are required.
These results support the concept that GVT is efficient against multiple myeloma and other LM who have been heavily pretreated even following relapse after ASCT. Such patients who are likely to be immunocompromised are most likely to engraft, develop GVHD and exhibit a GVT response following non-myeloablative allo-SCT. In this regard, the role of GVT effect against LM has been the subject of controversy over the years. In a large study by Kolb et al, 6 lymphocytic leukemia did not respond to adoptive immunotherapy with donor lymphocyte transfusions. In contrast, some observations of patients treated with DLI after failing myeloablative allogeneic transplantation, provide direct evidence of a potential GVT effect in patients with LM. 18, 19 Although with our approach, the decreased early transplant-related toxicity was replaced by GVHD morbidity and mortality, the high response rate observed in our short series is an important issue in trying to develop reduced intensity regimens for LM, since its effects do exist for lymphoid malignancies and it may be worth investigating strategies to generate more specific alloreactive effects in order to provide optimal GVT and an acceptable risk of GVHD and infectious complications.
